Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Chronic urticaria occurs in about 0.1% of the population (Greaves, 2000). Patients previously classified as having chronic idiopathic or "ordinary" urticaria are now divided into two groups: 40% ...

Some people have one flare-up and never get hives again. It’s also possible to have many flare-ups. If you continue to get hives daily or almost every day for six weeks or longer, you have chronic ...

Urticaria and angioedema are hives and the swelling that can accompany them. Learn about the triggers, including allergies and stress, and how to get relief. What Are Autoimmune Hives and What Causes ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

A search for thyroid auto-antibodies is appropriate for all chronic urticarias not responding to first-line therapies with antihistamines, especially when autoimmune urticaria is suspected.

According to GlobalData,... Likelihood of Approval and Phase Transition Success Rate Model - Rilzabrutinib in Chronic Urticaria Or Hives Rilzabrutinib is under clinical development by Sanofi and ...

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

but can now point to a win for rilzabrutinib in chronic spontaneous urticaria (CSU). In a phase 2 trial, rilzabrutinib has been shown to rapidly reduce itch severity and significantly improve ...